GENOR BIOPHARMA DL-00002 (67N0) - Net Assets

Latest as of June 2025: €1.10 Billion EUR ≈ $1.28 Billion USD

Based on the latest financial reports, GENOR BIOPHARMA DL-00002 (67N0) has net assets worth €1.10 Billion EUR (≈ $1.28 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.32 Billion ≈ $1.55 Billion USD) and total liabilities (€226.09 Million ≈ $264.32 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read 67N0 total debt and obligations for a breakdown of total debt and financial obligations.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€1.10 Billion
% of Total Assets	82.93%
Annual Growth Rate	-22.69%
5-Year Change	N/A
10-Year Change	N/A
Growth Volatility	13.25

GENOR BIOPHARMA DL-00002 - Net Assets Trend (2021–2024)

This chart illustrates how GENOR BIOPHARMA DL-00002's net assets have evolved over time, based on quarterly financial data. Also explore 67N0 total assets for the complete picture of this company's asset base.

Annual Net Assets for GENOR BIOPHARMA DL-00002 (2021–2024)

The table below shows the annual net assets of GENOR BIOPHARMA DL-00002 from 2021 to 2024. For live valuation and market cap data, see GENOR BIOPHARMA DL-00002 market capitalisation.

Year	Net Assets	Change
2024-12-31	€1.15 Billion ≈ $1.35 Billion	-3.28%
2023-12-31	€1.19 Billion ≈ $1.39 Billion	-34.04%
2022-12-31	€1.81 Billion ≈ $2.11 Billion	-27.59%
2021-12-31	€2.49 Billion ≈ $2.91 Billion	--

Equity Component Analysis

This analysis shows how different components contribute to GENOR BIOPHARMA DL-00002's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 145585900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Other Components	€7.99 Billion	694.16%
Total Equity	€1.15 Billion	100.00%

GENOR BIOPHARMA DL-00002 Competitors by Market Cap

The table below lists competitors of GENOR BIOPHARMA DL-00002 ranked by their market capitalization.

Company	Market Cap
Cashbil JSE:CSB	$132.56 Million
PPX Mining Corp V:PPX	$132.56 Million
NINtec Systems Limited NSE:NINSYS	$132.58 Million
GoldQuest Mining Corp. V:GQC	$132.59 Million
Protech Mitra Perkasa Tbk PT JK:OASA	$132.40 Million
Yatas Yatak ve Yorgan Sanayi Ticaret AS IS:YATAS	$132.34 Million
Origin Property PCL BK:ORI	$132.33 Million
SPRINGFIELD PROP. LS-125 F:9MZ	$132.26 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in GENOR BIOPHARMA DL-00002's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 1,188,814,000 to 1,151,479,000, a change of -37,335,000 (-3.1%).
Net loss of 51,283,000 reduced equity.
Other factors increased equity by 13,948,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	€-51.28 Million	-4.45%
Other Changes	€13.95 Million	+1.21%
Total Change	€-	-3.14%

Book Value vs Market Value Analysis

This analysis compares GENOR BIOPHARMA DL-00002's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.10x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2021-12-31	€4.96	€0.22	x
2022-12-31	€3.59	€0.22	x
2023-12-31	€2.36	€0.22	x
2024-12-31	€2.23	€0.22	x

Capital Efficiency Dashboard

This dashboard shows how efficiently GENOR BIOPHARMA DL-00002 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -4.45%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -24.87%
• Asset Turnover: 0.16x
• Equity Multiplier: 1.12x
Recent ROE (-4.45%) is above the historical average (-34.11%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2021	-34.75%	0.00%	0.00x	1.15x	€-1.11 Billion
2022	-40.51%	-4583.32%	0.01x	1.17x	€-910.46 Million
2023	-56.73%	0.00%	0.00x	1.22x	€-793.24 Million
2024	-4.45%	-24.87%	0.16x	1.12x	€-166.43 Million

Industry Comparison

This section compares GENOR BIOPHARMA DL-00002's net assets metrics with peer companies in the same industry.

Industry Context

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
GENOR BIOPHARMA DL-00002 (67N0)	€1.10 Billion	-34.75%	0.21x	$132.48 Million
Covestro AG (1COV)	$5.38 Billion	33.92%	1.06x	$11.10 Billion
2invest AG (2INV)	$63.16 Million	2.50%	0.02x	$70.69 Million
COINSHARES I. LS-000247 (3TW)	$269.95 Million	-1206.08%	19.01x	$472.53 Million
Adaptimmune Therapeutics plc (473A)	$341.23 Million	-38.12%	0.32x	$42.94 Million
KINGMAN MINERALS LTD. (47A)	$1.24 Million	-16.26%	0.60x	$701.35K
Biotest Aktiengesellschaft (BIO)	$480.20 Million	4.00%	1.15x	$976.15 Million
Biotest Aktiengesellschaft (BIO3)	$307.61 Million	12.84%	1.06x	$656.94 Million
Bancolombia S.A (BXK)	$39.05 Trillion	15.66%	7.78x	$4.84 Billion
mVISE AG (C1V)	$5.57 Million	-20.37%	2.06x	$10.43 Million

About GENOR BIOPHARMA DL-00002

F:67N0 Germany

Market Cap

$132.48 Million

€113.32 Million EUR

Market Cap Rank

#18235 Global

#1702 in Germany

Share Price

€0.22

Change (1 day)

-2.70%

52-Week Range

€0.22 - €0.57

All Time High

€2.90